Monoclonal Antibodies: A Gold Rush Among Drug Manufacturers
"The commercial success achieved by Monoclonal Antibodies in the last five years cannot be matched by any other drug class. Imarc expects this robust growth to continue in the next five years, driven primarily by a rich late stage pipeline and a strong demand from patients having high unmet therapeutic needs."
View full press release